Tau Capital has cut the value of Stopharm again and will now vale this investment at $8m. Tau Capital say the devaluation of the Tenge in February made Stopharm’s imports of pharmaceuticals (most of which are priced in euros or US dollars) more expensive without automatically allowing it to raise prices in Tenge as sales prices in Kazakhstan tend to be fixed for 12 months.
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated